• INOVIO Pharmaceuticals (NASDAQ:INO) is set to participate in two significant investor conferences in December, aiming to highlight its strategic initiatives.
• The company maintains an "Overweight" rating from Piper Sandler, with a recent stock price adjustment from $1.95 to $1.79.
• These conferences offer INOVIO an opportunity to engage directly with investors and discuss near-term catalysts that could influence its stock price.

INOVIO Pharmaceuticals, trading on NASDAQ under the symbol INO, is a biotechnology company focused on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. The company is gearing up for two major investor conferences in December. These events provide a platform for INOVIO to showcase its strategic initiatives and engage with investors.

The first event is the Piper Sandler 37th Annual Healthcare Conference on December 2 in New York. INOVIO will participate in a fireside chat, which will be available via a live webcast and replay for 90 days. Piper Sandler recently maintained an "Overweight" rating for INO, with the stock priced at $1.95 at the time of the announcement.

INOVIO will also attend the Oppenheimer Movers in Rare Disease Summit on December 11. The company will join a panel featuring elevator pitches from rare disease companies, discussing key near-term catalysts. Currently, INO's stock price is $1.79, reflecting a 5.29% decrease from the previous price of $1.95.

During these conferences, INOVIO's management will hold one-on-one meetings with investors. This is an opportunity to provide insights into the company's developments. INO's stock has fluctuated between $1.78 and $1.90 today, with a market capitalization of approximately $95.93 million.

Over the past year, INO's stock has seen a high of $4.61 and a low of $1.30. The trading volume on the NASDAQ exchange is 1,073,702 shares. These conferences could potentially impact stock movements, as highlighted by the company's participation in discussions on near-term catalysts.